Introduction
Intestinal fibrosis is generally considered a common consequence of inflammatory bowel disease (IBD), but may develop into a serious complication potentially leading to bowel obstruction and surgery [1 ] . The lack of a better understanding of its pathophysiology is striking when compared with our continuously expanding knowledge of immunopathogenic events in IBD. This ignorance is largely responsible for our current inability to diagnose intestinal fibrosis early and accurately, treat it properly, and take measures to prevent it. This review will discuss the most recent basic and clinical science developments in IBD-associated intestinal fibrosis.
Basic science
This section presents advances made in our understanding of fibroblast function and in identifying novel mediators of tissue fibrosis, but also in detecting additional sources of intestinal fibroblasts and developing new animal models of intestinal fibrosis.
Fibroblast function and mediators of tissue fibrosis
Exposure of mucosal fibroblasts (also termed myofibroblasts) to inflammatory mediators, and the subsequent collagen production and tissue remodeling are considered key events in the development of IBD-associated fibrosis [ [7] . Therefore, as for TNF-a, blockade of IL-21 may also be beneficial in preventing or reducing intestinal fibrosis (Fig. 1 ).
TGF-b1 is considered the most potent mediator of fibrosis through its direct effect on fibroblasts. TGF-b1 function is regulated at different levels, and intriguing new data suggest that the intestinal flora can modulate its profibrotic activity, as shown in a model of hepatic fibrogenesis in which toll-like receptor (TLR)-4 activation augments the TGF-b1-mediated collagen accumulation [8 ] . TLRs are expressed by intestinal fibroblasts [9] and are activated by a number of specific ligands (authors' unpublished observation). This observation places TGF-b1 under a new light, by subjecting its profibrotic activity to the control of the gut flora. IL-13 has also recently emerged as a profibrotic cytokine in several organs. This also appears to be true in the gut, as CD4þ T helper 2-derived IL-13 can cause TGF-b1-dependent intestinal fibrosis in the trinitrobenzene sulfonic acid (TNBS) colitis model [10 ] (Fig. 1 ).
In addition to classical cytokines, intestinal fibroblasts can be activated by noncytokine products, such as epithelial cell-derived galectin-3 [11 ] (Fig. 1 ). Galectin-3-induced activation is mediated by nuclear factor kB (NFkB), whose blockade with antisense oligonucleotides [12] or deoxyoligonucleotides [13] reduces both inflammation and fibrosis in the TNBS colitis model. A recent report by Wu and Chakravarti [14] extended these observations by showing that blocking the p65 subunit of NF-kB with antisense oligonucleotides reduces gut inflammationinduced fibrosis.
In addition to being the target of profibrotic mediators, fibroblasts themselves can produce factors promoting fibrosis, such as osteopontin. A recent study [15 ] shows that knockdown of the osteopontin gene in inflammationassociated skin fibrosis leads to wound healing with less scarring. If a similar response were observed in IBD it could open the door to prevention or eradication of intestinal fibrosis. Finally, the Wnt pathway is a central regulator of cell growth and differentiation, and it also appears to play a role in the pathogenesis of fibrotic diseases, as recently suggested by elevated levels of Wnt proteins in the development of age-dependent fibrosis [16 ] . This report suggests that investigation of the Wnt pathway in IBD could yield new insights into the mechanisms of intestinal fibrosis (Fig. 1 ). Intestinal fibrosis is characterized by fibroblast accumulation secondary to local proliferation and migration, differentiation from intestinal stellate cells, and recruitment from the bone marrow. Fibroblasts, however, can also derive from alternative sources such as circulating fibrocytes and transformation of epithelial and endothelial cells.
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Fibrocytes
Fibrocytes are bone marrow-derived circulating mesenchymal progenitors that coexpress hematopoietic and mesenchymal cell markers and produce ECM components [17 ] . During inflammation, fibrocytes are released from the bone marrow and migrate to affected sites, where they differentiate into epithelial, endothelial, neuronal and mesenchymal cells [17 ] . A link between the recruitment of fibrocytes to injured sites and tissue fibrosis has been established in various animal models [18] [19] [20] . Thus, in inflammation there is not only recruitment of immune and inflammatory cells but also mesenchymal cell precursors. How much fibrocytes contribute to intestinal fibrosis should be explored in animal models of IBD (Fig. 2) .
Epithelial-and endothelial-to-mesenchymal transition
Throughout the body a significant amount of fibroblasts are generated by the transformation of nonmesenchymal into mesenchymal cells. One example is epithelial-tomesenchymal transition (EMT), which occurs in embryonal, inflammatory or neoplastic conditions, and is characterized by dramatic changes in cell phenotype and function [21] . Epithelial cells take up a spindle-shape morphology, lose classical epithelial cell markers and gain typical fibroblast markers, like fibroblast-specific protein-1, a-smooth muscle actin, vimentin, and acquire the capacity to produce interstitial collagens and fibronectin.
Changes in migratory capacity and an increased resistance to apoptosis also occur [22] . EMT contributes to organ fibrosis in various tissues. In the adult liver hepatocyes can undergo EMT and transform into activated fibroblasts [23, 24] , an event that can be reverted by antagonizing TGF-b1 signaling with the bone morphogenetic protein-7 (BMP-7) [23] . Endothelial-tomesenchymal transition (EndoMT) is a similar form of cellular transformation relevant to fibrosis. Frid et al. [25] demonstrated that adult endothelial cells can differentiate into smooth muscle cells in vitro, and in a mouse model for cardiac fibrosis it has been calculated that endothelial cells contribute up to one-third of the total pool of tissue-infiltrating fibroblasts [26 ] .
Information on the contribution of EMT and EndoMT to IBD-associated fibrosis has yet to be published. The fact that the cardiac and intestinal vascular systems bear striking developmental, functional and morphological similarities [27] , and the abundant presence of soluble mediators of EndoMT in gut inflammation, however, make it likely that EndoMT occurs in IBD.
Animal models of intestinal fibrosis
Animal models are invaluable to study the pathogenesis of intestinal fibrosis and test new agents to prevent its development without impairing wound healing. As in humans, inflammation is a prerequisite for development of fibrosis in animal models of IBD, such as chronic dextran sulfate sodium colitis or peptidoglycan polysaccharide-induced small bowel inflammation [28] .
Other models for intestinal fibrosis have recently been described. Adenovirus-induced overexpression of TGF-b1 leads to colonic inflammation accompanied by differentiation of fibroblasts into smooth muscle cells, bowel wall thickening and massive ECM deposition with obstruction [29] . Using a similar adenovirus-driven system, overexpression of the chemokine MCP-1 also results in transmural gut inflammation and fibrosis [30] .
Chronic TNBS administration triggers intestinal fibrosis characterized by transmural inflammation, stricture formation and proximal dilatation, resembling what occurs in Crohn's disease [12] . Further characterization of this model shows that, after stopping TNBS, the expression of genes related to inflammation, acute phase response, and cell proliferation declines [14] . This correlates with less inflammation but, interestingly, the expression of genes encoding fibrosis-related proteins remains elevated. This suggests that fibrosis-related genes remain activated after inflammation subsides, implying that fibrosis may still develop after clinical control of active IBD. Emerging evidence indicates that mesenchymal cell targeting by TNF-a is sufficient to develop Crohn's disease-like lesions in the TNFDare mouse, identifying activation of mucosal fibroblasts as a key step driving the transition of acute-to-chronic inflammation and fibrosis [31] .
Clinical science
The ultimate goal of a better understanding of the mechanisms of intestinal fibrosis is to translate discoveries from basic sciences into clinical practice. This section presents new findings in risk assessment, diagnosis, and therapy of patients with intestinal fibrosis.
Risk assessment
Identifying risk factors for fibrotic stricture formation is essential for optimal patient management. Lichtenstein et al. [32] investigated factors potentially predictive of stricture formation in Crohn's disease patients enrolled in the TREAT registry and ACCENT I study, identifying disease duration and clinical severity as the most important factors. A retrospective study of 432 patients [33] identified symptomatic adhesions, residual strictures, lack of effective medical therapy, and severe disease unresponsive to medical treatment as clinical indicators for rapid reoperation.
Noninvasive tests that may predict complications like fistulae or stenosis would obviously be very desirable. Antibodies against the outer membrane porin protein C of Escherichia coli (anti-OmpC), bacterial flagellin (CBir1) and bacterial sequence I2 (anti-I2) are common in Crohn's disease patients, and the presence of multiple seropositivities has been associated with an increased risk for fibrostenotic small bowel involvement [34] . This association has been confirmed in a large cohort of eastern European patients [35] . Anti-CBir1 antibodies are independently associated with the Crohn's disease fibrostenotic phenotype and the presence of NOD2 variants [36] . A new association with antibodies against glycan epitopes, like laminaribioside (ALCA), chitobioside (ACCA) and mannobioside (AMCA), has been reported in a group of 1225 IBD patients [37 ] . Increased serum levels of these antibodies correlated with complicated disease and higher frequency of Crohn's diseaserelated surgery. Serum levels of the chitinase-like protein YKL-40 is also increased in Crohn's disease patients with strictures compared with those without strictures [38] . In agreement with the above retrospective studies in adults, one prospective study in children with IBD confirmed more rapid progress to complicated disease, including stricturing disease, when serum reactivity to anti-I2, anti-OMPc, anticBir1 or antiSaccharomyces cerevisiae antibody is present [39] .
Diagnosis
Current imaging techniques for identifying strictures secondary to bowel fibrosis are inadequate. The increased utilization of videocapsule endoscopy (VCE) may help to detect small bowel strictures in Crohn's disease patients, but a suspected stricture is in itself a contraindication to its use because of possible obstruction. To obviate this complication the Given Patency capsule has been developed. This device is a radio-tagged, radio opaque sham capsule endoscope, consisting of compressed lactose, which in case of retention and obstruction disintegrates in the lumen. This system could be used to determine luminal patency even in those patients with known small bowel stenosis. Spada et al. [40] prospectively tested the safety of VCE in 27 patients with known or suspected intestinal stricture previously tested by the Given Patency capsule. Patients passing the lactose-covered capsule (65%) underwent subsequent VCE without any complications, including those with tight strictures, only one patient requiring hospitalization due to temporary occlusion. Double-balloon enteroscopy (DBE) is a system consisting of a video enteroscope and a flexible overtube used for the examination of the small bowel. Sun et al. [41] prospectively investigated the value of DBE for the diagnosis of incomplete small bowel obstruction in patients without previous history of abdominal surgery. This technique identified the cause of obstruction in 93.1% of all patients examined, and Crohn's disease was responsible in 24.1% of cases. Similar findings were reported in a retrospective multicenter study of 179 patients [42] , Crohn's disease being the most common cause of small intestinal strictures.
New radiological approaches are being increasingly explored as means to detect intestinal fibrosis and its complications. Computed tomographic enterography (CTE) has been applied to examine the transmural nature and extent of Crohn's disease. Higgins et al. [43] retrospectively assessed its value in clinical practice and decision-making, and concluded that clinical parameters of inflammation do not correlate with CTE findings, but CTE can detect strictures beyond those clinically suspected and exclude clinically suspected strictures. Due to its noninvasive nature, radiological modalities are highly desirable, and several are under investigation, including magnetization transfer MRI, magnetic resonance elastography, and ultrasound elastography.
Therapy
Despite major progress in the overall treatment of IBD, the incidence of stricture formation and stenosis, and the need for bowel resection have not significantly changed during the last few decades [44] . Several nonsurgical procedures are now available for the treatment of strictures, including endoscopic balloon dilation (EBD), polyvinyl over-the-guidewire dilatation, endoscopic strictureplasty using metallic stents, and local injection of glucocorticoids [2 ,45] . While these procedures offer the advantage of being less invasive and preserving intestinal length, they usually offer only short-term relief. Ajlouni et al. [46] summarized the outcome of a series of 37 Crohn's disease patients with small bowel stricture treated with EBD in regard to success, safety, need for surgery, and long-term outcome. The overall results were favorable, EBD being successful in 90% of patients in terms of preventing re-stenosis and safety. This favorable outcome was attributed to the experience of the endoscopist, the selection of strictures, the size of the balloon, and the use of antibiotics. Most Crohn's disease patients with strictures treated conservatively will require repeated dilation and eventually surgery [47] . To improve long-term effectiveness, injection of anti-inflammatory or antifibrotic agents into predilated structures has been proposed as a complementary approach. East et al. [48 ] carried out a prospective controlled trial testing local injections of triamcinolone versus placebo in the prevention of postballoon dilatation recurrent stricturing in 13 patients with Crohn's disease. Unexpectedly, the results showed a trend towards earlier need for re-intervention when triamcinolone was used, leading to an early termination of the trial. This report contrasts with more promising results of previous retrospective but uncontrolled series [49, 50] , leaving the clinician uncertain about optimal treatment strategies. At the moment steroid injection after dilatation should be reserved for randomized controlled clinical trials [47] .
While systemic administration of anti-TNF-a is generally considered effective in patients with active Crohn's disease [51] , concern has been raised about the development or worsening of strictures in some patients. Sorrentino et al. [52, 53] recently reported the safe administration of infliximab in Crohn's disease patients with known fibrotic strictures, and another study found no association between infliximab and the development of strictures [32] . Injection of infliximab directly into a Crohn's disease stricture has been tested as a way to increase drug concentration at the site of disease. In an open-label pilot study three patients with no previous response to systemic infliximab received injections of this anti-TNF-a agent into colonic strictures. All patients showed resolution of symptoms and endoscopic improvement within 2 weeks and remained asymptomatic for 4, 6 or 7 months, respectively [54] . Based on the above reports, Crohn's disease-associated intestinal stenoses alone should no longer be regarded as an absolute contraindication to systemic or local treatment with anti-TNFa agents.
Unlike stenosis in the ileocolic or colonic region, most small bowel strictures cannot be easily reached by an endoscope. In addition to its diagnostic potential, DBE is now being proposed as a new therapeutic approach to small bowel strictures [55] . The use of DBE in 19 Crohn's disease patients with severe gastrointestinal stenoses showed sufficient safety and feasibility with a technical success rate of 80%, comparable to that obtained with dilatation of ileocolonic strictures. In another series DBE therapy avoided surgery in six of 13 patients with tight fibrotic small bowel strictures due to Crohn's disease [56] . Fukumoto et al. [42] claimed a long-term success of DBE dilatation of 74% over a period of 12 months in Crohn's disease patients without serious complications.
While the above new approaches to the management of Crohn's disease-associated strictures are encouraging, they are not danger free [57] , and additional studies are necessary before indications and contraindications can be firmly defined. In the mean time, the investigation of drugs that counteract the development of fibrosis to prevent stricture formation is certainly justified. Tranilast, N-(3 0 ,4 0 -dimethoxycinnamoyl) anthranilic acid, is a substance able to inhibit the ECM remodeling enzymes MMPs and TIMP-1, and has been shown to inhibit fibrosis in some experimental models [58, 59] . Oshitani et al. [60] administered Tranilast to 12 Crohn's disease patients with asymptomatic intestinal stenosis, and reported an increase in symptom-free time as well as the diameter of the stricture lumen compared with placebo.
Conclusion
An improved approach to prevent or reduce the complications secondary to intestinal fibrosis in IBD must rely on a greater understanding of its mechanisms of induction and persistence. Compared with the impressive advances that we have witnessed in the last decade in regard to unraveling the molecular and cellular mechanisms of mucosal inflammation, progress in both basic and clinical investigation of intestinal fibrosis has been relatively limited. Nevertheless, novel mediators of fibroblast activation and tissue remodeling, as well as novel sources for fibroblast recruitment, have been identified. Clinical, laboratory, endoscopic and radiological methods are being explored so that an early diagnosis can be made and a specific management of IBD-associated intestinal fibrosis can be developed independently of the sole control of intestinal inflammation.
